Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02413801 · ClinicalTrials.gov registry record
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients
A clinical trial of Psoriasis, sponsored by University of Rochester.
- Completed
- Registry status
- 103
- Enrollment target
- 1
- Study location
NCT02413801 is a study of Psoriasis that has completed, run by University of Rochester. The registered enrollment target is 103 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02413801, a study of Psoriasis, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
The events that underlie the conversion from Psoriasis to Psoriatic Arthritis (PsA) are not well understood. This conversion occurs 30% of the time within the first 10 years of psoriasis diagnosis. PsA patients have about a 50% chance of developing joint damage within the first 2 years of disease. A biomarker that identifies subclinical joint inflammation in psoriasis patients would allow for a diagnostic tool to allow for earlier intervention in psoriasis patients and provide a better understanding of the underlying molecular pathogenesis that may lead to development of new therapeutic targets in PsA.
Conditions Studied
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2015-03-19 |
| Est. Completion | 2023-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02413801
The ClinicalTrials.gov registry entry for NCT02413801 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (79% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 0 interventions.
NCT02413801 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02413801 about?
NCT02413801 is a clinical study titled "Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients". The events that underlie the conversion from Psoriasis to Psoriatic Arthritis (PsA) are not well understood. This conversion occurs 30% of the time within the first 10 years of psoriasis diagnosis. PsA patients have about a 50% chance of developing joint damage within the first 2 years of disease. A...
What is the current status of trial NCT02413801?
This trial is currently completed. The enrollment target is 103 participants. The study started on 2015-03-19. Estimated completion is 2023-12.
What conditions does trial NCT02413801 study?
This clinical trial studies the following conditions: Psoriasis.
Who is sponsoring clinical trial NCT02413801?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02413801 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.